Hepatology

Filter

liver disease

Liver Disease Risk Persists After Colorectal Cancer

January 2026

Patients who survive colorectal cancer face a sustained and increased risk of death from chronic liver disease and cirrhosis long after surgery, according to a large population-based analysis from the United States.

liver disease

Liver Disease Risk Persists After Colorectal Cancer

Patients who survive colorectal cancer face a sustained and increased risk of death from chronic liver disease and cirrhosis long after surgery, according to a large population-based analysis from the United States.

liver enzyme

Elevated liver enzyme levels increase Type 2 Diabetes risk

A Japanese cohort study has identified distinct liver enzyme trajectories in early adulthood that are strongly associated with the risk of developing type 2 diabetes.

Hepatitis B

Rethinking Endpoints in Chronic Hepatitis B Treatment

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically meaningful responses that improve patient outcomes, even without full antigen clearance.

Fetal Liver

Fetal Liver Organoids Recreate Human Immune–Liver Co-Development In Vitro

By reconstructing a fetal liver–specific niche, FLOs enable simultaneous development of hepatic and hematopoietic lineages, revealing cross-talk essential for understanding human liver development and immune injury.

AI ECG Screening Improves Liver Cirrhosis Detection - EMJ

AI-Based ECG Screening Boosts Liver Cirrhosis Detection

AI-enhanced ECG screening uncovers silent liver cirrhosis, enabling earlier diagnosis and intervention in routine primary care.

Recurrence Pattern Predicts Outcomes After Curative Resection for Hepatocellular Carcinoma

A long-term study shows that recurrence beyond the Milan criteria, rather than recurrence itself, drives poorer survival after curative hepatocellular carcinoma resection.

Nomogram Predicts Long-Term Liver Cancer Risk After Hepatitis C Cure

Study shows DAAs and interferon offer similar long-term protection against hepatocellular carcinoma after hepatitis C cure and introduces a nomogram to predict 8-year HCC risk.

Elafibranor Shows Promise for Primary Sclerosing Cholangitis

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing cholangitis, supporting further trials.

Loading posts...

1 2 3 … 41 Next »